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Abstract
Objective: Although bipolar disorder is a major contributor to functional impairment worldwide, an independent impact of bipolar 
disorder and ageing on functioning has yet to be demonstrated. The objective of the present study was to evaluate the effect of bipolar 
disorder on age-related functional status using matched controls as a standard. Method: One-hundred patients with bipolar disorder and 
matched controls were evaluated for disability. Age-related effects controlled for confounders were cross-sectionally evaluated. Results: 
Patients were significantly more impaired than controls. Regression showed effects for aging in both groups. The effect, size, however, 
was significantly stronger in patients. Conclusion: Bipolar disorder was an important effect modifier of the age impact on functioning. 
While a longitudinal design is needed to effectively demonstrate this different impact, this study further depicts bipolar disorder as a 
chronic and progressively impairing illness.
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Resumo
Objetivo: O transtorno bipolar é responsável por importante parcela do prejuízo funcional ao redor do mundo. Um efeito independente 
do transtorno bipolar e da idade no funcionamento ainda não foi demonstrado. O presente estudo tem o objetivo de avaliar o efeito 
do transtorno bipolar no prejuízo funcional relacionado à idade, com controles pareados como padrão. Método: Cem pacientes com 
transtorno bipolar e controles pareados foram avaliados para incapacidade. Efeitos relacionados à idade, com controle para confundidores, 
foram investigados. Resultados: Pacientes tiveram significativamente mais prejuízo que controles. A regressão mostrou efeito para a 
idade em ambos os grupos, e o efeito foi significativamente mais forte nos pacientes. Conclusão: O transtorno bipolar foi um importante 
modificador de efeito no impacto da idade no funcionamento. Enquanto um desenho de estudo longitudinal é necessário para efetivamente 
demonstrar este impacto diferencial, este estudo caracteriza o transtorno bipolar como uma doença crônica e incapacitante.
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Introduction
Ageing is often associated with progressive disability, with unique 
environment and genetics impacting age-related functioning.1 
Among the mood disorders, bipolar disorder (BD) is associated 
with functioning within or below the functioning levels of the 
most chronic illnesses;2 moreover, it could increase age-related 
impairment through both genetic and environmental pathways. 
An increased allostatic load associated with BD would anticipate 
such an association.3 This concept is akin to cumulative physiologic 
dysregulation and allows for the prediction of changes in physical 
and cognitive functioning.4 
To our knowledge, an independent impact of bipolar disorder on 
age-related functioning has yet to be demonstrated in a controlled 
study. We evaluated this effect, with matched healthy subjects as a 
standard against which age-related impairment was measured.
Method
One-hundred outpatients with a confirmed diagnosis of BD 
according to the Structured Clinical Interview for DSM-IV and 
healthy controls individually matched for gender, age and years 
of education were consecutively recruited from September to 
November 2007. The only ground for exclusion was the inability 
to provide informed consent. Thus, patients were representative of 
patients treated for bipolar disorder in a tertiary health care centre. 
Compared to other outpatients in the Bipolar Disorders Programme 
of the Hospital de Clínicas de Porto Alegre5 (n = 260), the patients 
in this study were not significantly different in terms of their age 
(44.23 vs 42.63), gender (74% vs 70% female) and number of 
hospitalizations (3.57 vs 3.57). All participants gave their written 
informed consent before entering the study, which was approved 
by the local ethics committee. 
Functional impairment was assessed using the Functioning 
Assessment Short Test (FAST), an interview that evaluates disability. 
It includes items on autonomy, work, cognitive functioning, financial 
issues and interpersonal relationships. It has excellent reliability and 
was checked regarding content, construct and concurrent validity 
in Brazilian and Spanish populations.6,7
We used multiple linear regression with robust estimation of 
variances in the patient and control groups separately to test for 
age effects on functioning. In these analyses, effects were controlled 
for potential disability-related confounders,8 such as medications 
currently in use and affective symptoms, which were assessed using 
the Hamilton Depression Rating Scale, the Young Mania Rating 
Scale and the Hamilton Anxiety Rating Scale  and hospitalizations. 
We also tested inthe model years since diagnosis and years since 
specific treatment, but these were not predictive of functioning. 
Coefficients (β) and standard errors (SE) from these regressions were 
used to generate effect sizes. Heterogeneity, that is, how much the 
groups differ was investigated with the Q statistic. When the p value 
for this statistic is low (below conventional levels of significance), 
the hypothesis of homogeneity is rejected and one can conclude 
that one is not measuring an effect of the same size.9 Wilcoxon’s 
signed rank test (Z) was used to compare FAST scores in patients 
and controls. All tests are two-tailed.
Results
Groups were well matched (Table 1). Patients were significantly 
more impaired than control subjects (n = 200, Z = 8.19, 
p < 0.001). This effect was sustained even when only those 
on monotherapy (n = 30, Z = 2.33, p = 0.019), with no past 
hospitalizations (n = 36, Z = 3.40, p < 0.001) or with no 
significant depressive symptoms (HAMD < 8; n = 104, Z = 5.34, 
p < 0.001) were considered.
Figure 1 displays the unadjusted impact of BD on age-related 
functioning. In the regression analyses, age was significantly 
associated with functioning both in patients (β = 0.377, 
SE = 0.087, p < 0.001) and control subjects (β = 0.101, 
SE = 0.039, P = 0.013). These effects were significantly different 
(Q = 8.37, p = 0.004). 
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Discussion
Bipolar illness is characterized by a course both cyclic and recurrent, 
but to what extent it is progressive is still surrounded by considerable 
controversy. While some argue that there is a lack of evidence of 
progressive worsening,10 others argue that accelerated biological 
ageing does take place in BD.11 In this study, bipolar disorder was 
an important effect modifier of age effects on functioning, further 
characterizing BD as a chronic and impairing illness. 
As this was not a population-based sample, extrapolating these 
findings to less severely affected patients may be problematic. 
Additionally, controlled longitudinal studies are needed to confirm 
these differential age-related effects on functioning. Notwithstanding 
the limitations of the cross-sectional design employed, we did find 
a significant, noteworthy and independent impact of BD on age-
related functioning. 
Emerging evidence suggests that cognition does play a role in 
these effects as accelerating hippocampal grey matter loss has been 
prospectively demonstrated in BD.12 Since an increased allostatic 
load creates a risk for cognitive decline,4 may be the end result of 
cumulative physiologic dysregulation related to medical burden,13 
HPA axis dysfunction,14 altered immunity, pro-inflammatory15 and 
oxidative stress states.16 These factors may be partially modifiable 
medical risks and potential targets to reduce increasing morbidity 
and impairment in bipolar disorder. 
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